Here is a brand new one..
Canadian Company Press Release
SYB 1999-07-09 (provided courtesy of Canadian Corporate News.)
register to receive future releases by email from CCN
SYNSORB Biotech Inc. Appoints New Director
CALGARY, ALBERTA--SYNSORB Biotech Inc. ("SYNSORB") (TSE: SYB;
Nasdaq: SYBB) today announced the appointment of Richard L. Casey,
formerly of Scios Inc., to the Company's Board of Directors.
Mr. Casey has over 25 years of experience in the pharmaceutical
industry, and most recently served as Chairman, President and CEO
for Scios Inc., a biopharmaceutical company engaged in the
discovery, development, manufacture and commercialization of novel
human therapeutics. A New Drug Application for Scios' lead
product for congestive heart failure is currently being reviewed
by the USFDA.
Prior to joining Scios in 1987, Mr. Casey served as the President
of Alza Pharmaceuticals Division, a company that develops and
markets specialized drug delivery products. From 1976 to 1985,
Mr. Casey held various positions within Syntex, including Director
of Market Research, Vice President of Sales, and General Manager
of the Medical Diagnostics Division. Prior thereto, he held
various sales and marketing roles with Eli Lilly.
Mr. Casey retired from Scios in 1998 and is currently serving on
the Board of Directors of Guilford Pharmaceuticals, a
biotechnology company focussed on diseases of the Central Nervous
System.
"Mr. Casey's experience in bringing products through the
development phase and establishing corporate partnerships are
critical to SYNSORB," said Dr. Brad Thompson, Chairman of the
Board in announcing the appointment. "We are extremely pleased to
welcome Mr. Casey to SYNSORB's Board of Directors."
SYNSORB is dedicated to accelerated drug development from the
acquisition of promising compounds emerging from basic research
through clinical development, and ultimately to providing channels
to market for new discoveries. Headquartered in Calgary, SYNSORB
currently has two products in late stage clinical development,
SYNSORB Pk(R) for the prevention of HUS and the treatment of
verotoxigenic E. coli (VTEC) infections (including O157:H7), and
SYNSORB Cd(R) designed to treat recurrent antibiotic-associated
diarrhea (CDAD). SYNSORB has additional compounds in pre-clinical
development, including REOSYN, a potential cancer treatment being
developed within its subsidiary company, Oncolytics Biotech Inc.,
and novel antibiotics, with inflammation and anti-virals targeted
in the Company's research and development program.
Shares of SYNSORB Biotech Inc. trade on the Toronto Stock Exchange
in Canada (symbol "SYB") and on NASDAQ in the United States
(ticker "SYBB").
This release contains certain forward-looking statements which
involve known and unknown risks, delays, uncertainties and other
factors not under the Company's control which may cause actual
results, performance or achievements of the Company to be
materially different from the results, performance or other
expectations implied by these forward-looking statements. These
factors include results of current or pending clinical trials,
actions by the FDA/HPB and those factors detailed in the Company's
registration statement on Form 20 F filed with the Securities and
Exchange Commission.
-30-
FOR FURTHER INFORMATION PLEASE CONTACT:
SYNSORB Biotech Inc.
Dr. David Cox
President & CEO
(403) 283-5900
(403) 283-5907 (FAX)
synsorb.com
or
The Equicom Group
Jason Hogan
Investor Relations
(416) 815-0700 ex 222
(416) 815-0080 (FAX)
jhogan@equicomgroup.com
|
